Page 22 - Read Online

65. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, 79. Morelli MP, Calvo E, Ordoñez E, Wick MJ, Viqueira BR,
Shafait S, Lau A, Cranston AN, O’Connor MJ, Huntsman DG, Lopez-Casas PP, Bruckheimer E, Calles-Blanco A,
Wang Y, Gilks CB. Tumor growth inhibition by olaparib in Sidransky D, Hidalgo M. Prioritizing phase I treatment
BRCA2 germline-mutated patient-derived ovarian cancer options through preclinical testing on personalized tumorgraft.
tissue xenografts. Clin Cancer Res 2011;17:783-91. J Clin Oncol 2012;30:e45-8.
66. Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived 80. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC,
xenograft models to improve targeted therapy in epithelial Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA,
ovarian cancer treatment. Front Oncol 2013;3:295. McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR,
67. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Goodman KM, Sarkaria JN, Karlan BY, Kumar A,
Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Kaufmann SH, Hartmann LC, Haluska P. Tumorgrafts as
Gilks B, Yerushalmi R, Macpherson E, Carmichael J, in vivo surrogates for women with ovarian cancer. Clin Cancer
Oza A. Olaparib in patients with recurrent high-grade serous Res 2014;20:1288-97.
or poorly differentiated ovarian carcinoma or triple-negative 81. Hidalgo M, Bruckheimer E, Rajeshkumar NV,
breast cancer: A phase 2, multicentre, open-label, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S,
non-randomised study. Lancet Oncol 2011;12:852-61. Wick MJ, Martell J, Sidransky D. A pilot clinical study of
68. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Löhr GW. treatment guided by personalized tumorgrafts in patients with
Comparison of tumor response in nude mice and in the advanced cancer. Mol Cancer Ther 2011;10:1311-6.
patients. Behring Inst Mitt 1984;74:343-52. 82. Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse
69. Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor chimeric models for the evaluation of anti-cancer therapies.
growth stimulation in human tumors in vitro following Trends Immunol 2001;22:386-93.
treatment with recombinant human growth hormone. 83. Hylander BL, Punt N, Tang H, Hillman J, Vaughan M,
Anticancer Drugs 2000;11:659-64. Bshara W, Pitoniak R, Repasky EA. Origin of the vasculature
70. Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts supporting growth of primary patient tumor xenografts.
as model for drug testing. Cancer Metastasis Rev 1988;7:263-84. J Transl Med 2013;11:110.
71. Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, 84. Klemm F, Joyce JA. Microenvironmental regulation of
Desjardins L, Piperno-Neumann S, Lantz O, Asselain B, therapeutic response in cancer. Trends Cell Biol 2014; doi:
Plancher C, Robert D, Peguillet I, Donnadieu MH, 10.1016/j.tcb.2014.11.006.
Dahmani A, Bessard MA, Gentien D, Reyes C, Saule S, 85. Pickup MW, Mouw JK, Weaver VM. The extracellular
Barillot E, Roman-Roman S, Decaudin D. Establishment matrix modulates the hallmarks of cancer. EMBO Rep
and characterization of a panel of human uveal melanoma 2014;15:1243-53.
xenografts derived from primary and/or metastatic tumors. 86. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD,
Clin Cancer Res 2010;16:2352-62. Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R,
72. Peterson JK, Houghton PJ. Integrating pharmacology and Yokota SJ. Humanized mouse model of ovarian cancer
in vivo cancer models in preclinical and clinical drug recapitulates patient solid tumor progression, ascites formation,
development. Eur J Cancer 2004;40:837-44. and metastasis. PLoS One 2011;6:e24420.
73. Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, 87. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV,
Peterson JK, Friedman HS, Billups C, Houghton PJ. Relation Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK,
between Irofulven (MGI-114) systemic exposure and tumor Manz MG, Flavell RA. Development and function of
response in human solid tumor xenografts. Clin Cancer Res human innate immune cells in a humanized mouse model.
2002;8:3000-7. Nat Biotechnol 2014;32:364-72.
74. Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, 88. Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C,
Klar U, Hoffmann J. Comparative profi ling of the novel Selva E, Merino-Trigo A, Venissac N, Mouroux J, Vrignaud P,
epothilone, sagopilone, in xenografts derived from primary Hofman P. Setting up a wide panel of patient-derived tumor
non-small cell lung cancer. Clin Cancer Res 2010;16:1452-65. xenografts of non-small cell lung cancer by improving the
75. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, preanalytical steps. Cancer Med 2015;4:201-11.
Theil FP, Tibbitts J, Friedman LS, Hop CE, Gould SE. 89. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT,
Antitumor activity of targeted and cytotoxic agents in murine Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM,
subcutaneous tumor models correlates with clinical response. Roman-Roman S, Seoane J, Trusolino L, Villanueva A.
Clin Cancer Res 2012;18:3846-55. Patient-derived xenograft models: An emerging platform for
76. Malaney P, Nicosia SV, Davé V. One mouse, one patient translational cancer research. Cancer Discov 2014;4:998-1013.
paradigm: New avatars of personalized cancer therapy. Cancer 90. Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M,
Lett 2014;344:1-12. Wen D, Zhu Y, Qin X. Establishment and characterization of 7
77. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. novel hepatocellular carcinoma cell lines from patient-derived
The APL paradigm and the “co-clinical trial” project. Cancer tumor xenografts. PLoS One 2014;9:e85308.
Discov 2011;1:108-16.
78. Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, How to cite this article: Li G. Patient-derived xenograft models for
Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, oncology drug discovery. J Cancer Metastasis Treat 2015;1:8-15.
Harding V, Vasquez D, Krell J, Ciznadija D, Katz A,
Sidransky D. Patient-derived xenografts for individualized Received: 05-11-2014; Accepted: 27-01-2015.
care in advanced sarcoma. Cancer 2014;120:2006-15. Source of Support: Nil, Confl ict of Interest: None declared.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦ 15